A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects With Active Rheumatoid Arthritis (RA).

Trial Profile

A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects With Active Rheumatoid Arthritis (RA).

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2012

At a glance

  • Drugs LX 2931 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Aug 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
    • 31 Jul 2012 Status changed from active, no longer recruiting to completed, according to a Lexicon Pharmaceuticals media release.
    • 07 Mar 2012 Planned end date changed from 1 Dec 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top